| Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma N Ahmed, VS Brawley, M Hegde, C Robertson, A Ghazi, C Gerken, E Liu, ... Journal of clinical oncology 33 (15), 1688, 2015 | 1011 | 2015 |
| HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial N Ahmed, V Brawley, M Hegde, K Bielamowicz, M Kalra, D Landi, ... JAMA oncology 3 (8), 1094-1101, 2017 | 704 | 2017 |
| Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape M Hegde, M Mukherjee, Z Grada, A Pignata, D Landi, SA Navai, ... The Journal of clinical investigation 126 (8), 3036-3052, 2016 | 632 | 2016 |
| TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy Z Grada, M Hegde, T Byrd, DR Shaffer, A Ghazi, VS Brawley, A Corder, ... Molecular Therapy-Nucleic Acids 2, 2013 | 513 | 2013 |
| Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma M Hegde, A Corder, KKH Chow, M Mukherjee, A Ashoori, Y Kew, ... Molecular Therapy 21 (11), 2087-2101, 2013 | 395 | 2013 |
| Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma K Bielamowicz, K Fousek, TT Byrd, H Samaha, M Mukherjee, N Aware, ... Neuro-oncology 20 (4), 506-518, 2018 | 375 | 2018 |
| Immunogenicity of CAR T cells in cancer therapy DL Wagner, E Fritsche, MA Pulsipher, N Ahmed, M Hamieh, M Hegde, ... Nature reviews Clinical oncology 18 (6), 379-393, 2021 | 164 | 2021 |
| Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma LK Donovan, A Delaidelli, SK Joseph, K Bielamowicz, K Fousek, ... Nature medicine 26 (5), 720-731, 2020 | 163 | 2020 |
| TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer TT Byrd, K Fousek, A Pignata, C Szot, H Samaha, S Seaman, ... Cancer research 78 (2), 489-500, 2018 | 139 | 2018 |
| CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression K Fousek, J Watanabe, SK Joseph, A George, X An, TT Byrd, JS Morris, ... Leukemia 35 (1), 75-89, 2021 | 137 | 2021 |
| Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma M Hegde, SK Joseph, F Pashankar, C DeRenzo, K Sanber, S Navai, ... Nature communications 11 (1), 3549, 2020 | 117 | 2020 |
| Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group RD Roberts, MM Lizardo, DR Reed, P Hingorani, J Glover, ... Cancer 125 (20), 3514-3525, 2019 | 101 | 2019 |
| T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1 S Krebs, KKH Chow, Z Yi, T Rodriguez-Cruz, M Hegde, C Gerken, ... Cytotherapy 16 (8), 1121-1131, 2014 | 89 | 2014 |
| Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma A Ghazi, A Ashoori, P Hanley, VS Salsman, DR Shaffer, Y Kew, SZ Powell, ... Journal of Immunotherapy (Hagerstown, Md.: 1997) 35 (2), 159, 2012 | 84 | 2012 |
| Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. N Ahmed, V Brawley, M Hegde, K Bielamowicz, A Wakefield, A Ghazi, ... Journal for immunotherapy of cancer 3, 1-1, 2015 | 63 | 2015 |
| Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas SA Navai, C Derenzo, S Joseph, K Sanber, T Byrd, H Zhang, M Mata, ... Cancer Research 79 (13_Supplement), LB-147-LB-147, 2019 | 48 | 2019 |
| Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma. M Hegde, CC DeRenzo, H Zhang, M Mata, C Gerken, A Shree, Z Yi, ... Journal of Clinical Oncology 35 (15_suppl), 10508-10508, 2017 | 44 | 2017 |
| Immunotherapy for pediatric brain tumors: past and present JB Foster, PJ Madsen, M Hegde, N Ahmed, KA Cole, JM Maris, ... Neuro-oncology 21 (10), 1226-1238, 2019 | 43 | 2019 |
| Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients A Wakefield, A Pignata, A Ghazi, A Ashoori, M Hegde, D Landi, T Gray, ... Journal of Neuro-oncology 125, 307-315, 2015 | 35 | 2015 |
| High incidence of autoimmune disease after hematopoietic stem cell transplantation for chronic granulomatous disease AD Yanir, IC Hanson, WT Shearer, LM Noroski, LR Forbes, FO Seeborg, ... Biology of Blood and Marrow Transplantation 24 (8), 1643-1650, 2018 | 29 | 2018 |
